Renaissance Capital logo

Vision loss biotech Aurion Biotech files for a $100 million IPO

January 24, 2025
Aurion Biotech logo

Aurion Biotech, a commercial-stage biotech developing regenerative cell therapies for eye diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

Aurion is focused on advancing a single administration, allogeneic cell therapy to treat vision loss due to corneal endothelial diseases. In Japan, its first-generation cell therapy product received regulatory and reimbursement approval, and launched commercially in September 2024 under the marketed name Vyznova. Its next-generation candidate, AURN001, is an improved formulation designed to be mechanistically identical to Vyznova and to provide enhanced benefits. The company has completed enrollment and dosed 97 subjects in a Phase 1/2 trial for AURN001 in the US and Canada, and 12-month data from this trial is expected in the 2H25.

The Seattle, WA-based company was founded in 2016 and booked $1 million in revenue for the 12 months ended September 30, 2024. It plans to list on the NYSE under the symbol AURN. Aurion Biotech filed confidentially on October 21, 2024. J.P. Morgan, BofA Securities, Piper Sandler, and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.